medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2018, Number 3

<< Back Next >>

Residente 2018; 13 (3)

Síndrome antifosfolípidos, nociones generales

Barreno-Rocha SG, del Ángel-Aranda AK, Muñoz-Gaytán DE, Aceves-Sanchezborjas JP, Guzmán-Silahua S, Rubio-Jurado B, Nava-Zavala AH

Language: Spanish
References: 14
Page: 98-103
PDF size: 213.96 Kb.


ABSTRACT

The antiphospholipid syndrome is a current issue on public health since it’s prevalence around 1-5% in the general population. This situation combined with the limited knowledge that we have about this disease places it’s placed in a matter of interest for the health sector. The clinic manifestations of this pathology could manifest in a wide range of symptoms and signs being the most representatives such as the arterial and venous thrombosis with more frecuency in the limbs and also fetal loss before the 10th week of pregnancy. For the diagnosis of this disease is necessary to prove the presence of thrombosis or fetal loss within the elevation of biomarkers of coagulation called antiphospholipids antibodies. The treatment for patients that present this pathology has been a challenge to found the balance between the hemorrhages or the development of the thrombotic disease.


REFERENCES

  1. Da Silva F, de Carvalho J. Rheumatic fever associated with antiphospholipid syndrome: systematic review. J Immunol Res. 2014; 2014: 614591.

  2. Gomez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun. 2014; 48-49: 20-25.

  3. Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018; 4: 17103.

  4. Amengual O, Atsumi T. Antiphospholipid syndrome, “the best prophet of the future”. Mod Rheumatol. 2018; 28 (3): 409-416.

  5. Lim W. Antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2013; 2013: 675-680.

  6. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013; 368 (11): 1033-1044.

  7. Lopes MRU, Danowski A, Funke A, Rego J, Levy R, Andrade DCO. Update on antiphospholipid antibody syndrome. Rev Assoc Med Bras (1992). 2017; 63 (11): 994-999.

  8. Kutteh WH. Antiphospholipid antibody syndrome and reproduction. Curr Opin Obstet Gynecol. 2014; 26 (4): 260-265.

  9. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010; 376 (9751): 1498-1509.

  10. Chaturvedi S, McCrae KR. The antiphospholipid syndrome: still an enigma. Hematology Am Soc Hematol Educ Program. 2015; 2015: 53-60.

  11. Voigtlaender M, Conradi L, Hinsch A, Langer F. Right atrial thrombosis in antiphospholipid syndrome with secondary immune thrombocytopenia. Thorac Cardiovasc Surg Rep. 2015; 4 (1): 40-43.

  12. Mikkiliineni VR, Panidapu N, Parasa M, Shaik MS. Anesthetic management in a case of antiphospholipid antibody syndrome. Anesth Essays Res. 2015; 9 (3): 411-412.

  13. Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R et al. The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody positive patients: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository. Arthritis Care Res (Hoboken). 2018.

  14. Sciascia S, Bertolaccini ML. Thrombotic risk assessment in APS: the Global APS Score (GAPSS). Lupus. 2014; 23 (12): 1286-1287.




2020     |     www.medigraphic.com